Menopause medicine: current treatment options and trends.
Demographic trends and increasing demand, as well as the intricacy of the emerging field of menopause medicine, dictates the need for a multidisciplinary approach for the care of the peri- and postmenopausal patient. A menopausal program benefits the individual patient by obviating the acute symptoms and by preventing long-term consequences. As morbidity and mortality rates associated with the long-term implications are reduced, substantial public health aspects are also beneficially affected. Cost effectiveness of a menopause program and routine HRT should be calculated as the net present value (NPV) for the health care financing program, and should prove to be greater than the NPV of future costs anticipated without an investment in primary preventive menopause program. We believe that the educated use of a menopause counseling program will yield an increasing benefit for the individual patient and the community. Should menopause be regarded as an endocrinopathy, thus justifying routine HRT, or are we engaged in the "medicalization" of a physiologic process? Bearing in mind the data reviewed above, it seems to us that ample reason exists to make every woman aware of the opportunity to receive long-term HRT. The decision to use it depends heavily on the patient's own informed assessment of her particular benefit-risk equation. Combined-continuous estrogen-gestagen replacement seems to provide the desired multisystem beneficial effects, and at the same time be the most convenient and associated with the least short-term side effects. Although emerging trends regarding the long-term risks associated with the use of such regimes are reassuring, more information needs to be elaborated before final conclusions can be offered.
Birkenfeld
A
A
Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, New York 10029.
Kase
N G
NG
D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D002985:Clinical Protocols / Q000592:standards; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000592:standards* / Q000639:trends; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D009369:Neoplasms / Q000139:chemically induced; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control